Compare · BDMD vs WST
BDMD vs WST
Side-by-side comparison of Baird Medical Investment Holdings Ltd (BDMD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDMD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.35B, about 362.6x BDMD ($61.6M).
- Over the past year, BDMD is down 66.9% and WST is up 51.0% - WST leads by 117.9 points.
- WST has been more active in the news (6 items in the past 4 weeks vs 2 for BDMD).
- WST has more recent analyst coverage (15 ratings vs 0 for BDMD).
- Company
- Baird Medical Investment Holdings Ltd
- West Pharmaceutical Services Inc.
- Price
- $1.45-1.70%
- $315.91-2.11%
- Market cap
- $61.6M
- $22.35B
- 1M return
- -16.95%
- +6.16%
- 1Y return
- -66.90%
- +51.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 6
- Recent ratings
- 0
- 15
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest BDMD
- SEC Form POS AM filed by Baird Medical Investment Holdings Ltd
- SEC Form F-3 filed by Baird Medical Investment Holdings Ltd
- SEC Form SCHEDULE 13G filed by Baird Medical Investment Holdings Ltd
- Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update
- SEC Form 20-F filed by Baird Medical Investment Holdings Ltd
- SEC Form 3 filed by new insider Xu Lijian
- SEC Form 3 filed by new insider Qiu Quan
- SEC Form 3 filed by new insider Lu Rongjian
- SEC Form 3 filed by new insider Bilciu-Wolfson Gabrielle
- SEC Form 3 filed by new insider Li Jie Clara
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
- Director Lai Goldman Myla was granted 791 shares, increasing direct ownership by 4% to 20,435 units (SEC Form 4)